Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026235 | 1.00 | F10 (0.85) | F10 | |
| SCHEMBL4029696 | 0.94 | F10 (0.85) | F10 | |
| SCHEMBL4029694 | 0.94 | F10 (0.85) | F10 | |
| SCHEMBL4030105 | 0.92 | F10 (0.88) | F10 | |
| SCHEMBL4030109 | 0.92 | F10 (0.88) | F10 | |
| SCHEMBL4029739 | 0.92 | F10 (1.00) | F10 | |
| SCHEMBL4029754 | 0.92 | F10 (1.00) | F10 | |
| SCHEMBL4029140 | 0.91 | F10 (0.91) | F10 | |
| SCHEMBL4029146 | 0.91 | F10 (0.91) | F10 | |
| SCHEMBL4028059 | 0.91 | F10 (0.85) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | claimed |
| EP-1562939-B1 | CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2009-01-21 | — | — | EP | claimed |
| US-20060052376-A1 | Carboxamides | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20060052376-A1 | Carboxamides | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052376-A1 | Carboxamides | F11, F12, F10 | F10 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.